Session 1 – Possible Avenues to Speed Up Patient Access

Complete Session 1

Government/Payer perspective – Anne Willemsen (EUnetHTA, NL)

Patient Perspective – Sabrina Hanna (the cancer collaborative, CA)

Academic Perspective – Bert Boer (Erasmus University Rotterdam, NL)

Industry Perspective – Ansgar Hebborn (Roche, CH)

Breakout Session, Room 1 – Speakers: Sabrina Hanna (the cancer collaborative, CA) and Anne Willemsen (EUNetHTA, NL)

Breakout Session, Room 2 – Speaker: Bert Boer (Erasmus University Rotterdam, NL)

Breakout Session, Room 3 – Speaker: Ansgar Hebborn (Roche, CH)

Session 2 – CDDF Workshops in 2021

Complete Session 2, including Q&A sessions

Why do we have endpoints in clinical trials? – Axel Glasmacher (CDDF, DE)

Digital Tools and AI in Oncology Drug Development – Dónal Landers (Digital Experimental Cancer Medicine Team, CRUK, Manchester Institute, UK)

Session 3 – Cancer Drug Development in a Global Setting

Complete Session 3, including the Panel Discussion

Pharmacogenetics in oncology – Ron Mathijssen (Erasmus MC, NL)

Tumour agnostic drug development and tumour-agnostic re-use of registered drugs – Richard L. Schilsky (ASCO, USA)

Regional matters on the road to global approvals – Irmela Radtke (Roche, CH)

A Regulatory Perspective – Angelo de Claro (FDA, USA)

Session 4 – Advances in Imaging

Complete Session 4, including the Q&A session

Radiology imaging – Marion Smits (Erasmus MC, NL)

Molecular imaging – Wim Oyen (Rijnstate Hospital Arnhem and Humanitas Univ Milan, NL)

Session 5 – Regulatory Hot Topics

Complete Session 5, including Q&A Sessions

Patients Preferences – Hans Hillege (Committee for Medicinal Products for Human Use, EMA, NL)

RWE: technical perspective – Sinan B. Sarac (Danish Medicines Agency, DK)